The drug was authorized to treat mild to moderate COVID-19 in adults who are at high risk of developing severe illness when alternative treatment options are not “not accessible or clinically appropriate,” Merck said.
The authorization is more limited than for Pfizer’s antiviral Paxlovid, which the FDA greenlit Dec. 22. Research shows Merck’s pill reduced the risk of hospitalization or death by 30 percent, while Pfizer’s lowered this risk by 88 percent, according to The New York Times.
The treatment consists of 40 pills taken over five days and should be available within the next few weeks.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.